Objective. Development of proteinuria in lupus nephritis (LN) is associated with podocyte dysfunction. The NLRP3 inflammasome has been implicated in the pathogenesis of LN. The purpose of this study was to investigate whether NLRP3 inflammasome activation is involved in the development of podocyte injury in LN.
proteinuria, renal histologic lesions, and podocyte foot process effacement in lupus-prone mice. In vitro, sera from diseased NZM2328 mice activated NLRP3 inflammasomes in the podocyte cell line through the production of reactive oxygen species.
Conclusion. NLRP3 inflammasomes were activated in podocytes from lupus-prone mice and from LN patients. Activation of NLRP3 is involved in the pathogenesis of podocyte injuries and the development of proteinuria in LN.
Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease. It occurs in women of childbearing age and often involves multiple organs. Lupus nephritis (LN) is one of the major manifestations of SLE. Although existing treatments were shown to improve the prognosis of LN, only 70-80% of treated patients responded well (1) . Indeed, 10-15% of LN patients experience progression to end-stage renal disease within 10 years (2) . In order to identify novel and effective therapeutic approaches, a better understanding of the pathogenic mechanism of LN is needed.
Podocytes are the major component of the glomerular filtration apparatus and are important for the maintenance of renal function. Proteinuria is one of the major features of LN, and the development of proteinuria is associated with podocyte dysfunction. Indeed, podocyte injuries are present in most LN patients (3) . Possible mechanisms include genetic factors, inflammation, toxic injury, and metabolic disturbances (4) . Although deposition of immune complexes and/or complement activation contributes to podocyte injury through the initiation of glomerular inflammation in LN, podocytes have rarely been considered a major player in these processes. The results of a recent study of diabetic nephropathy demonstrating the importance of activation of the NLRP3 inflammasome in non-myeloidderived cells suggest that podocytes are an active participant in the production of the inflammatory cytokine interleukin-1b (IL-1b), resulting in further recruitment of inflammatory cells (5) .
The NLRP3 inflammasome is an important member of the innate immune system. Many extracellular and endogenous danger signals can induce NLRP3 inflammasome activation and assembly (6) . After activation, the leucine-rich repeat (LRR) domain of NLRP3 binds to the ligand, causing oligomerization of NLRP3, recruiting the downstream adapter proteins ASC and procaspase 1 to form the NLRP3 inflammasome, which subsequently self-catalyzes procaspase 1 to become caspase 1, generating the active p10 and p20 fragments. Active caspase 1 can cleave inactive proIL-1b and proIL-18 into their mature forms (IL-1b and IL-18) and initiate inflammation (7) .
The NLRP3 inflammasome has been implicated in the pathogenesis of LN. We have shown that inhibition of NLRP3 inflammasome activation or blockage of its upstream P2X 7 receptor reduced proteinuria in lupusprone mice (8, 9) . However, it is not clear whether NLRP3 inflammasome activation is involved in podocyte injury in LN. In this study, we examined the role of NLRP3 activation in podocytes during LN induction.
PATIENTS AND METHODS
Animals. NZM2328 mice, a new NZM strain produced by extended backcrosses of (NZB 3 NZW)F1 mice with NZW mice (10) , were provided by the University of Virginia animal care facility and maintained in the specific pathogen-free colony at the Experimental Animal Center at Sun Yat-sen University. The study protocol was approved by the Ethics Committee of Sun Yat-sen University, and all experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences. Only female mice were used in this investigation.
Preparation of single-cell suspensions of glomeruli for fluorescence-activated cell sorting (FACS). Isolation of renal glomeruli and preparation of single-cell suspensions were performed as described by Takemoto et al (11) and modified by Sung et al (12) . Single-cell suspensions were stained for glomerular resident cells using anti-mouse phycoerythrin (PE)-conjugated CD26 (BioLegend), Alexa Fluor 647-conjugated nephrin (Bioss), PECy7-conjugated CD105 (eBioscience), PerCP-Cy5.5-conjugated CD31 (BioLegend), allophycocyanin-eFluor-conjugated CD45 (eBioscience), and a FAM-FLICA caspase 1 probe (ImmunoChemistry Technologies). All FACS analyses were done with a Gallios flow cytometer (Beckman Coulter). This procedure has been described in detail by Sung et al (12) .
Generation of an NZM2328 podocyte cell line and its response to stimulation with NZM2328 mouse sera. An immortalized podocyte cell line was generated by transfecting isolated podocytes from an NZM2328 mouse with severe proteinuria by use of the retrovirus containing the vector plpcx-SVtsa58, which has the temperature-sensitive SV40 (tsSV40) large T antigen. This vector has a puromycin-resistant gene as a selection marker, and it is similar to pZiptsa58 (13, 14) . The cell line plpcxtSVtsa58/TeFlyMo clone 24 was kindly provided by Dr. P. Jat (Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK). The supernatant of this clone has the desired packaged viral particles for transforming epithelial cells. Briefly, podocytes isolated from a female NZM2328 mouse with severe proteinuria were incubated with the supernatant from plpcxtSVtsa58/TeFlyMo clone 24 cells. The cells were cultured at 338C in an atmosphere containing 5% CO 2 in RPMI 1640 (Life Technologies) supplemented with 10% fetal calf serum (FCS; Gibco), 100 units/ml of penicillin, and 100 mg/ml of streptomycin on plates coated with rat tail type I collagen (SigmaAldrich). The cells were allowed to grow to confluence and digested with trypsin and plated at a density of 1 3 10 4 . Some of the cells were cloned by limiting dilution. One of the clones that were positive for nephrin was used in this study.
For maintenance of the podocyte cell line, undifferentiated podocytes were grown under permissive conditions at 338C in an atmosphere of 5% CO 2 in RPMI 1640 supplemented with 10% FCS, 100 units/ml of penicillin, and 100 mg/ml of streptomycin on plates coated with rat tail type I collagen. For differentiation, podocytes were cultured under growth-nonpermissive conditions at 378C in an atmosphere of 5% CO 2 in RPMI 1640 supplemented with 10% FCS, 100 units/ml of penicillin, and 100 mg/ml of streptomycin for 14 days.
Well-differentiated podocytes from the cell line were cultured in 6-cm culture dishes and treated with 4 different stimuli: phosphate buffered saline (PBS), sera from 12-week-old NZM2328 mice without proteinuria or anti-double-stranded DNA (anti-dsDNA) antibody, sera from 36-week-old NZM2328 mice with 31 proteinuria and anti-dsDNA antibody, and sera from 36-week-old NZM2328 mice without IgG, which had been depleted with Protein A/G Plus-Agarose (Beyotime Biotechnology). For NLRP3 inflammasome inhibition experiments, welldifferentiated podocytes were cultured and primed with 1 mM the selective NLRP3 inhibitor MCC950 (Selleck Chemicals) or 100 mM Mito TEMPO (Sigma Aldrich) for 1 hour in the presence or absence of sera from diseased mice for 12 hours. After this incubation, cells were subjected to flow cytometry and Western blotting for determination of NLRP3 inflammasome activation, mitochondrial membrane potential (DCm), and production of reactive oxygen species (ROS).
MCC950 treatment in vivo. MCC950 was diluted at 1 mg/ml in vehicle (saline solution). NZM2328 mice ages 20 weeks were randomized into 2 groups (n 5 8 per group): vehicletreated and MCC950-treated. Mice were treated with either MCC950 (10 mg/kg) or an equal volume of vehicle intraperitoneally every 2 days from age 20 weeks to age 26 weeks. Urine was collected every week. At the end of treatment, mice were anesthetized, and the kidneys were harvested and analyzed. Another 2 groups of mice (n 5 8 per group) were treated as described above for only 2 weeks. After treatment, single-cell suspensions of mouse kidneys were prepared and stained for flow cytometry.
Histology, immunofluorescence, and transmission electron microscopy (TEM) of mouse tissues. Mice were anesthetized and perfused through their hearts with 40 ml of cold PBS. For histologic examination, kidneys were fixed in 10% neutral formalin and embedded in paraffin for sectioning (2 mm), followed by staining with periodic acid-Schiff. Histopathologic evaluation was performed by 2 observers (CG and SW) who were blinded with regard to the protocol, as previously described (8) . Glomerular lesions were graded on a scale of 0 (normal) to 3 (severe cell proliferation/infiltration and crescent formation).
For confocal microscopy, frozen kidneys were fixed in acetone, and cryostat sections (4 mm) were obtained. Sections were washed 3 times with PBS and blocked for 30 minutes with 1% bovine serum albumin (BSA) in PBS. After blocking, sections were incubated with Alexa Fluor 555-conjugated polyclonal antimouse synaptopodin antibody (Santa Cruz Biotechnology), and a FAM-FLICA caspase 1 assay kit was used to detect caspase 1 activation in glomerular podocytes. After washings, the cells were mounted in Vectashield antifade mounting medium with DAPI (Vector). It should be noted that the polyclonal anti-mouse synaptopodin antibody also reacts with human synaptopodin. In this study, the antibody from Santa Cruz Biotechnology was used for both human and mouse tissues. A Zeiss LSM 710 confocal microscope was used for microscopy.
For TEM, kidney tissue was fixed in 2.5% glutaraldehyde and 2% paraformaldehyde (weight/volume) in 0.1M phosphate buffer, pH 7.4. The fixed tissue was processed for electron microscopy and examined with a Tecnai G 2 Spirit Twin electron microscope.
Analysis of proteinuria and measurement of renal IL-1b. Mouse urine samples were tested with proteinuria analysis strips (Albustix; Bayer). Six distinct colors indicate negative, trace, 30, 100, 300, and $2,000 mg/dl of protein. Urinary protein levels $300 mg/dl were designated as severe proteinuria. IL-1b in the renal protein extract was measured with an IL-1b enzymelinked immunosorbent assay kit (eBioscience) according to the manufacturer's protocol.
Western blot analysis. Kidney tissues and cells from the NZM2328 podocyte cell line were processed for Western blot analysis as described by Zhao et al (8) . Proteins were transferred onto a PVDF membrane (Merck Millipore). After blockade with 5% nonfat dry milk in Tris buffered saline-0.1% Tween 20 (TBST), the membranes were incubated overnight at 48C with the following antibodies: mouse anti-P2X 7 receptor (Abcam), mouse anti-NLRP3 (AdipoGen), rabbit anti-caspase 1-p20 (AdipoGen), and rabbit anti-GAPDH (Cell Signaling Technology) antibodies. After washing 3 times with TBST, blots were incubated with their corresponding secondary antibodies. Signals were detected with a chemiluminescence analysis kit (Thermo).
Human kidney immunofluorescence and urinary cell smears. Kidney biopsy was performed for diagnostic purposes, and samples were obtained from patients with LN (class IV and class V). Renal tissue dissected adjacent to a renal tumor was obtained from a patient undergoing therapeutic nephrectomy; this tissue was considered to be normal. Acetone-fixed cryostat sections (4 mm) of the kidneys were washed 3 times with PBS and blocked for 30 minutes with 1% BSA in PBS. For staining of human kidney sections, Alexa Fluor A647-conjugated antisynaptopodin antibody, FAM-FLICA caspase 1 probe, and Alexa Fluor A555-conjugated mouse monoclonal antibody against human IL-1b (R&D Systems) were used. Fresh morning urine samples (100 ml) were collected from LN patients with marked proteinuria and healthy volunteer donors and Figure 1 . Activation of the NLRP3 inflammasome in podocytes obtained from diseased NZM2328 mice. A, Expression of NLRP3 and caspase 1-p20 (normalized to GAPDH and caspase 1, respectively) in the kidneys of 36-week-old and 12-week-old NZM2328 mice, as demonstrated in representative Western blots (left) and the relative expression levels (right) in each group. B, Levels of interleukin-1b (IL-1b) in renal extracts of kidneys from NZM2328 mice. Glomeruli were isolated from NZM2328 mice and single-cell suspensions were prepared and analyzed. C and D, Levels of active caspase 1 in podocytes (C) and endothelial cells (D), as determined by flow cytometry. Values are the mean 6 SD of 3 mice per group. * 5 P , 0.05; ** 5 P , 0.01. MFI 5 median fluorescence intensity; NS 5 not significant. centrifuged for 10 minutes at 1,500 revolutions per minute. The pellets were washed 3 times with PBS and suspended in a small volume of Dulbecco's modified Eagle's medium (Life Technologies). The cells were spun onto slides by a cytospin centrifuge and fixed with acetone. The cells were stained with Alexa Fluor A555-conjugated antisynaptopodin antibody and FAM-FLICA caspase 1 probe or Alexa Fluor A488-conjugated mouse monoclonal antibody against human IL-1b. A Zeiss LSM 710 confocal microscope was used for microscopy.
Written informed consent was obtained from all subjects before study entry. The study was approved by the Ethics Committee of the First Affiliated Hospital, Sun Yat-sen University.
Statistical analysis. Statistical analysis was performed using SPSS 17.0 software. Results are expressed as the mean 6 SD. Differences were assessed by t-test or one-way analysis of variance. Chi-square analysis was performed to compare the incidence of severe proteinuria between groups. P values (2-tailed) less than 0.05 were considered statistically significant.
RESULTS
Activation of the NLRP3 inflammasomes in podocytes from diseased NZM2328 mice. The onset of severe proteinuria is observed in some female NZM2328 mice at 16 weeks of age. By 30 weeks of age, the cumulative incidence of severe proteinuria is ;70% (10). To assess whether NLRP3 inflammasomes were activated in mice with severe proteinuria, we evaluated 36-week-old NZM2328 mice (proteinuria 31). The diseased mice had circulating anti-dsDNA antibodies. We used 12-week-old NZM2328 mice (proteinuria-negative without anti-dsDNA antibodies) as controls. Enhanced expression of NLRP3 and activated caspase 1, which was detected as caspase 1-p20, was observed in the kidneys of the 36-week-old NZM2328 mice but not the 12-week-old NZM2328 mice ( Figure 1A ). Renal IL-1b levels in the 36-week-old NZM2328 mice were significantly higher than those in the 12-week-old NZM2328 mice ( Figure 1B) .
Glomeruli were isolated, and single-cell suspensions were prepared from mice of both age groups. A fluorescence-labeled inhibitor probe (FAM-FLICA caspase 1) that specifically binds to intracellular active caspase 1 was used to measure levels of active caspase 1 in renal cells. The median fluorescence intensity (MFI) of active caspase 1 in nephrin-positive podocytes from the 36-week-old NZM2328 mice was significantly higher than that in the 12-week-old NZM2328 mice ( Figure 1C ). There was no significant difference in the MFI of active caspase 1 in CD31-positive endothelial cells from the two groups ( Figure 1D ).
Activation of NLRP3 inflammasome in renal podocytes from biopsy tissues obtained from LN patients. We next examined whether NLRP3 inflammasome activation is also present in podocytes from LN patients. With the use of a fluorescence-labeled antisynaptopodin antibody to mark podocytes and a FAM-FLICA caspase 1 probe to label active caspase 1 enzyme, confocal microscopy revealed the colocalization of synaptopodin and active caspase 1 in the kidney biopsy samples from LN patients.
Nine patients with class IV LN and 4 patients with class V LN were studied. In all cases, activation of the NLRP3 inflammasome was detected in podocytes. Representative images of class IV and class V LN samples are presented in Figure 2 . As shown in Figure 2A , activation of Figure 3 . Activated NLRP3 inflammasomes in podocytes derived from the urine of patients with lupus nephritis (LN). Fresh urine was collected, and cells were spun onto a cytospin slide. An antisynaptopodin antibody (red), a FAM-FLICA caspase 1 probe (green), and an antihuman interleukin-1b (IL-1b) monoclonal antibody (green) were used to detect active caspase 1 and IL-1b in urinary podocytes. DAPI was used to stain nuclei (blue). Caspase 1 (A) and IL-1b (B) were expressed in urinary podocytes from LN patients but not normal subjects. Original magnification 3 630.
1640
FU ET AL the NLRP3 inflammasome was not detected in the podocytes of normal kidneys, and there was no staining for IL-1b. Both NLRP3 inflammasome activation and IL-1b expression were present in the tubular cells, however. In contrast, both activation of the NLRP3 inflammasome and expression of IL-1b were readily detected in samples from both class IV and class V LN kidneys ( Figures 2B and C) . It is of note that the intensity of staining for caspase 1 and IL-1b was similar in class IV and class V specimens. The staining of tubular cells for both caspase 1 and IL-1b was stronger in LN kidneys than in normal kidneys. Activated NLRP3 inflammasome in urinary podocytes. To further confirm activation of the NLRP3 inflammasome in podocytes from LN patients, we examined podocytes in the urine of patients with active LN and normal individuals. As shown in Figure 3 , podocytes identified in the urine by synaptopodin staining were seen in both normal volunteers and patients with LN. Colocalization of synaptopodin and active caspase 1 was observed only in the urinary podocytes from patients with active LN ( Figure  3A ). There was also colocalization of synaptopodin with IL-1b in these urine cells ( Figure 3B ). Podocytes from the urine of healthy volunteers did not stain for active caspase 1 or IL-1b. These findings were observed in 5 patients with class IV LN and in 3 healthy controls.
Reduced caspase 1 activation after MCC950 treatment in podocytes from NZM2328 mice. MCC950, a selective NLRP3 inhibitor, was used to treat NZM2328 mice. Following 6 weeks of treatment, the expression of NLRP3 and caspase 1-p20, the active form of caspase 1, was significantly inhibited as compared to the vehicle group ( Figures 4A-C) . MCC950 treatment significantly reduced the production of IL-1b in the kidneys ( Figure 4D ). Fluorescence-conjugated antisynaptopodin antibody and a FAM-FLICA caspase 1 probe were then used to detect active caspase 1 expression in glomerular podocytes. As shown in Figure 4E , podocytes from mice treated with vehicle had brighter green staining than did those from the MCC950-treated group (Figure 4E ), suggesting that activation of caspase 1 was inhibited by MCC950. The MFI of active caspase 1 in both podocytes and endothelial cells was significantly reduced following MCC950 treatment ( Figures 4F and G) . It appears that MCC950 did not significantly block the activation of caspase 1 in the tubular cells.
Reduced proteinuria and renal lesions after MCC950 treatment in NZM2328 mice. We further assessed the effects of inhibition of NLRP3 activation in podocytes during the onset of proteinuria. As shown in Figure 5A , vehicle-treated NZM2328 mice began to present severe proteinuria ($31) from 23 weeks of age (week 3 after the start of vehicle treatment). Compared with the vehicle-treated group, the proportion of mice with severe proteinuria was significantly lower in the MCC950-treated group. Transmission electron microscopy showed that MCC950 treatment significantly attenuated foot process effacement ( Figure 5B ). The glomerular histologic findings were also significantly improved in the treated group, which showed lower histopathology scores ( Figures 5C and D) .
Activation of the NLRP3 inflammasome in podocytes from NZM2328 mice after treatment with serum from diseased NZM2328 mice. To ascertain the role of autoantibodies in NLRP3 activation in podocytes, cells of the NZM2328 podocyte cell line were stimulated with sera from diseased NZM2328 mice. Compared to pooled control sera and PBS, sera from mice with severe proteinuria and anti-dsDNA antibodies were shown to activate NLRP3 inflammasomes in the NZM2328 podocyte line, as determined by Western blotting ( Figure 6A ) and by flow cytometry ( Figure 6C ), and to increase the production of IL-1b ( Figure 6B ). The production of ROS, as measured with 2 0 ,7 0 -dichlorodihydrofluorescein diacetate ( Figure  6D ), was significantly increased, and mitochondrial membrane potentials, as measured with rhodamine 123 ( Figure  6E ), were significantly decreased in cells treated with pooled sera from mice with severe proteinuria. However, the expression of P2X 7 receptor was not elevated after stimulation with pooled sera from diseased mice ( Figure  6F ). Furthermore, MCC950, which specifically inhibits NLPR3 inflammasome activation (15) , and MitoTempo, a mitochondria-targeted antioxidant, significantly inhibited activation of the NLRP3 inflammasome ( Figures 6A and  C) and the production of IL-1b ( Figure 6B ). Additional experiments were carried out using IgG-depleted serum from diseased mice. IgG-depleted serum samples failed to activate caspase 1, suggesting that the active component in the sera from diseased mice was IgG ( Figure 6G ). 
DISCUSSION
Podocytes are highly specialized cells located outside the basement membrane of glomeruli. They express markers such as synaptopodin, Wilms' tumor protein, glomerular epithelial protein 1, and nephrin. These molecules play important roles in maintaining filtration barrier Figure 6 . Activation of the NLRP3 inflammasome in podocytes treated with sera from diseased NZM2328 mice. The NZM2328 podocyte cell line was stimulated for 24 hours with phosphate buffered saline (PBS), control serum, serum from a diseased NZM2328 mouse, or IgG-depleted serum from a diseased NZM2328 mouse in the presence or absence of MCC950 or MitoTempo. A, Caspase 1-p20 expression in representative Western blots (left) and relative expression levels (normalized to caspase 1) (right), in podocytes from each group. B, Levels of interleukin-1b (IL-1b) in supernatants treated with the same stimuli as in A. Values are the mean 6 SD. * 5 P , 0.05; ** 5 P , 0.01. C-E, Levels of active caspase 1 (C), production of reactive oxygen species (D), and the mitochondrial membrane potential (E) of podocytes, as determined by flow cytometry using caspase 1, dichlorodihydrofluorescein diacetate (DHCF-DA), and rhodamine 123, respectively. F, Expression of purinergic receptor P2X 7 , as determined by Western blotting. G, Expression of caspase 1-p20 following stimulation with serum from a diseased mouse or IgG-depleted serum from a diseased mouse. NS 5 not significant; MFI 5 median fluorescence intensity.
integrity (16) . With the identification of podocyte-specific markers, it is now feasible to study the podocyte response to injuries in various disease states. In this study, we used biomarkers to isolate intrinsic renal cells from a mouse model of lupus nephritis. We documented that NLRP3 is activated in podocytes in patients with LN in response to immunologic injury. However, the mechanisms by which these processes relate to podocyte injury remain to be elucidated. Nevertheless, our observations document that podocytes play an active role in the disease process in LN, adding credence to our long-held hypothesis that endorgan resistance to damage under genetic control plays an important role in the pathogenesis of LN (17, 18) .
Our observations provide the impetus to focus more on investigating intraglomerular cellular interactions in the pathogenesis of LN. In this regard, it would be of interest to determine whether similar observations would be made in female NZM2328.c1R27 (R27) mice (19) , which are resistant to the progression of proliferative immune complex-mediated nephritis to severe proteinuria and endstage renal disease. This is of particular relevance in view of our recent observation that unique intraglomerular macrophages (CD11b1F4/80-I-A-) are seen in NZM2328 mouse kidneys with chronic glomerulonephritis and severe proteinuria but not in those from R27 mice (12) .
The exact mechanism of podocyte injury is not yet fully elucidated. Inflammation has been implicated in the podocyte dysfunction in renal diseases with proteinuria (4) . In this study, by using a probe for active caspase 1, we showed the activation of NLRP3 inflammasomes in podocytes from human LN renal biopsy tissues and in urinary podocytes. Activation of the NLRP3 inflammasome was also confirmed in isolated primary podocytes from lupus-prone NZM2328 mice with severe proteinuria. In contrast, no activation of NLRP3 was found in podocytes from NZM2328 mice without proteinuria. Our results may favor the interpretation that the activation of inflammasomes is associated with podocyte injury in LN. Moredefinitive evidence may be forthcoming with the generation of a conditional knockout of NLPR3 in podocytes in the NZM2328 mouse.
Much interest has recently focused on the activation of the NLRP3 inflammasome in kidney disease and autoimmunity (20) (21) (22) . Using a similar approach as that in the present study, Xiong et al (20) demonstrated the activation of caspase 1 in podocytes in patients with focal segmental glomerulosclerosis, mesangial proliferative glomerulonephritis, and membranous nephropathy. To a lesser degree, some podocytes in patients with IgA nephropathy were shown to express caspase 1. The latter finding corroborates the recent observation that NLRP3 localized to the tubular epithelium in human kidneys correlates with outcome in IgA nephropathy (23) .
Activation of the NLRP3 inflammasome in tubular cells has been considered a mechanism of kidney damage in acute and chronic kidney injuries caused by ischemiareperfusion injury, drugs, rhabdomyolysis, glucose, crystals, and unilateral nephrectomy (21, 22, 24) . Little information is available regarding the role of podocyte responses with regard to these insults in the kidney. In the present study, caspase 1 activation was seen in the tubular cells of normal kidneys, and this activation was enhanced in the tubular cells from renal biopsy tissues from patients with class IV and class V LN. It remains to be determined whether this activation contributes significantly to the pathogenesis of LN or is the byproduct of proteinuria (25) .
The role of NLRP3 in adaptive immunity should also be considered. Hutton et al (21) considered the major effect of the NLRP3 inflammasome on adaptive immunity to be through its modulating effects on T helper cell subsets, skewing development in favor of Th17 and Th1 cells. Since few T cells reside within the glomeruli, the effects of intraglomerular NLRP3 inflammasome activation may not have much effect on the overall intrarenal T cell subsets. On the other hand, because most infiltrating renal T cells are located in the periglomerular region, the activation of NLRP3 inflammasomes in tubular and interstitial cells may have paramount effects on T cells. It should be noted that in the MCC950-treated mice, activation of the NLRP3 inflammasome was not significantly down-regulated in the tubular and interstitial cells. This observation suggests that with our treatment protocol, activation of NLRP3 inflammasomes may not have been affected in the interstitium. The Th1 and Th17 cell subsets in the kidneys of MCC950-treated and vehicle-treated mice may therefore be similar. The effect of NLRP3 inflammasome activation on adaptive immunity can be ascertained by assaying Th1 and Th17 subsets in kidneys treated with MCC950.
Our study documents that IL-1b is expressed by podocytes as a result of NLRP3 activation. IL-1b is a potent proinflammatory cytokine and has been shown to repress nephrin promoter activity and the transcription of nephrin in podocytes (26) . The down-regulation of nephrin expression may interfere with the integrity of podocytes as a filtration barrier, providing a mechanism for podocyte injury and renal impairment. In the present study, podocytes were shown to express IL-1b in both renal tissues and urinary podocytes from patients with LN. This observation supports the previous observation that podocytes are the major source of IL-1b in human and rat glomerulonephritis (27, 28) . Together with our published results, our present observation that treatment of NZM2328 mice with the specific NLRP3 inhibitor 1644 FU ET AL MCC950 suppresses the activation of NLRP3 in podocytes, resulting in reduced podocyte foot process effacement. Decreased proteinuria would again support the thesis that IL-1b would be a target in the treatment of LN. This is particularly relevant in repositioning approved drugs for the treatment of LN in view of the approval of IL-1 receptor antagonist (IL-1Ra) for the treatment of rheumatoid arthritis.
There are conflicting results regarding the effectiveness of IL-1Ra in the treatment of glomerulonephritis. IL-1Ra is effective in preventing the development of antiglomerular basement membrane (anti-GBM) nephritis as well as in the treatment of established anti-GBM nephritis (29) (30) (31) . However, it has been reported that it is not effective in reversing established nephritis in MRL/lpr mice (32) . It was partially effective in treating nephritis in (NZB 3 NZW)F1 mice (33) . Our previously published data (8, 9) and the results of the present investigation indicate that targeting the NLRP3/IL-1b pathway is beneficial in treating LN in mouse models. In view of the recent observation that inhibition of IL-1 receptor signaling prevented or even reversed diabetic nephropathy in mice (5), further investigation is needed to determine whether targeting the NLRP3/IL-1b signaling pathway would be beneficial in the treatment of LN.
NLRP3 inflammasomes can be activated by a variety of stimuli; among them, mitochondrial injury is a common and most important intracellular stimulus (34) . When mitochondria are injured or stressed, the mitochondrial membrane potential decreases, resulting in the release of harmful molecules such as ROS. These molecules then activate NLRP3 inflammasomes and up-regulate IL-1b and IL-18, thus exacerbating inflammation (35) . In our study, sera from diseased lupus-prone mice activated NLRP3 inflammasomes and increased the production of IL-1b in podocytes from the NZM2328 cell line but did not interfere with the expression of K 1 channel P2X 7 receptor, an upstream molecule of the NLRP3 pathway. In addition, the mitochondrial membrane potential was shown to decrease with significantly increased production of ROS. The activation of NLRP3 inflammasomes was inhibited by mitochondrial ROS inhibitors. These findings indicate that sera from diseased mice activated NLRP3 inflammasomes through ROS generated by injured mitochondria.
Thus far, we have documented that the active component in the sera of diseased mice is IgG. How these IgG molecules cause mitochondrial damage remains to be determined. One plausible mechanism is that these IgG molecules enter podocytes via neonatal Fc receptor (FcRn). This mechanism is supported by the recent observation that IgG from lupus patients entered podocytes via the FcRn receptor and up-regulated Ca 21 /calmodulindependent protein kinase IV, which was followed by increased expression of genes related to podocyte damage and T cell activation (36) . It should be clear that other mechanisms are plausible.
Podocytes appear in the urine of healthy subjects, and increased urinary excretion of podocytes (podocyturia) is found in proteinuric states (37) . Urinary podocytes have been used to assess disease activity in LN (38) . In this study, we identified urinary podocytes according to positive staining for activated caspase 1 and IL-1b. Whether such podocytes are associated with disease activity in the kidneys of patients with SLE needs further investigation.
In conclusion, our studies show that NLRP3 inflammasomes are activated in podocytes of both LN patients and lupus-prone mice. Activation of NLRP3 is involved in the pathogenesis of podocyte injury and the development of proteinuria in LN. In addition, our findings support the idea that targeting the NLRP3/IL-1b pathway for the treatment of LN may hold promise.
